<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548454</url>
  </required_header>
  <id_info>
    <org_study_id>44758</org_study_id>
    <nct_id>NCT03548454</nct_id>
  </id_info>
  <brief_title>Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization</brief_title>
  <official_title>Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 100 million Americans suffer from chronic pain resulting in annual cost of roughly $635&#xD;
      billion. Limited treatments are available for this widespread disease. The data supporting&#xD;
      these treatments lack generalizability to patients with more serious medical and&#xD;
      psychological comorbidities who are often excluded from explanatory efficacy trials. Our work&#xD;
      aims to integrate randomized comparative effectiveness research with patient care. The&#xD;
      investigators will randomize the patients and collect data using an open-source learning&#xD;
      healthcare system already in use in our department to monitor patients' progress:&#xD;
      Collaborative Health Outcomes Information Registry (CHOIR). Collaborative Health Outcomes&#xD;
      Information Registry uses the National Institute of Health Patient Reported Outcomes&#xD;
      Measurement Information System item banks for comparative metrics through computer adaptive&#xD;
      testing. The investigators will leverage the advantage of this novel system to compare&#xD;
      effectiveness of duloxetine and desipramine in decreasing pain in patients with chronic pain.&#xD;
      The investigators will also compare adherence of patients to these two commonly used&#xD;
      medications over a period of six months. This will evaluate feasibility of integrating&#xD;
      randomized comparative effectiveness research with patient care in subspecialty clinics.&#xD;
      Collaborative Health Outcomes Information Registry can then be applied for numerous future&#xD;
      trials to advance our knowledge in perioperative and pain medicine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>Average and worst pain intensity reported by participants on a numerical rating scale of 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical Function</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for physical function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Interference</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for pain interference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>Time to stopping either medication in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desipramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Open label prescription</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desipramine</intervention_name>
    <description>Open label prescription</description>
    <arm_group_label>Desipramine</arm_group_label>
    <other_name>Norpramin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Age of 18 years old or above&#xD;
&#xD;
          2. Persistent pain for more than 3 months&#xD;
&#xD;
          3. Candidate for treatment by anti-depressant based on treating pain provider&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Prior failure of duloxetine and/or desipramine (patients who have failed other TCAs or&#xD;
             SNRIs can be considered for the trial based on the reason for previous medication&#xD;
             failure)&#xD;
&#xD;
          2. Contraindication to taking duloxetine or desipramine&#xD;
&#xD;
          3. Patient refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vafi Salmasi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vafi Salmasi, MD.</last_name>
    <phone>650-725-0246</phone>
    <email>vsalmasi@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Pain Management Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vafi Salmasi, MD.</last_name>
      <phone>650-725-0246</phone>
      <email>vsalmasi@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Vafi Salmasi</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Desipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

